Incyte Biosciences Denmark ApS: Financial statements 2015
CVR: 35818790
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
Incyte Biosciences Denmark ApS (CVR 35818790) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 1,532,406 and a net result of DKK 26,475. Equity in the 2015 report amounted to DKK 81,881. The solvency ratio was 8.3%.
- Gross Profit
- DKK 1,532,406
- Profit/Loss
- DKK 26,475
- Equity
- DKK 81,881
- Total Assets
- DKK 986,717
Official annual report
How creditworthy is Incyte Biosciences Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
Incyte Biosciences Denmark ApS has published its interim report for the period April 1, 2014 to December 31, 2014.
About Incyte Biosciences Denmark ApS
Incyte Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Frederiksberg C, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ARIAD PHARMACEUTICALS (DENMARK) ApS. The management consists of Ebba Cecilia Bröms. The board consists of Lee Jason Heeson (chair) and Ebba Cecilia Bröms. The company is owned by Incyte Biosciences International Sàrl. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. Equity in the 2025 report amounted to DKK 2,328,496.